Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease

Taisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, JapanCorrespondence: Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunky...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ishii T, Tanaka T, Nangaku M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	prolyl hydroxylase domain hypoxia inducible factor erythropoietin iron Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/f7bc19af972b4ef4b01564c2effb0336
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7bc19af972b4ef4b01564c2effb0336
record_format	dspace
spelling	oai:doaj.org-article:f7bc19af972b4ef4b01564c2effb03362021-12-02T14:16:09ZProfile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease1178-203Xhttps://doaj.org/article/f7bc19af972b4ef4b01564c2effb03362021-02-01T00:00:00Zhttps://www.dovepress.com/profile-of-daprodustat-in-the-treatment-of-renal-anemia-due-to-chronic-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XTaisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, JapanCorrespondence: Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 1138655, JapanTel +81-3-3815-5411Fax +81-3-5800-9826Email mnangaku-tky@umin.ac.jpAbstract: Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxia-inducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.Keywords: prolyl hydroxylase domain, hypoxia-inducible factor, erythropoietin, ironIshii TTanaka TNangaku MDove Medical Pressarticleprolyl hydroxylase domainhypoxia inducible factorerythropoietinironTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 155-163 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prolyl hydroxylase domain hypoxia inducible factor erythropoietin iron Therapeutics. Pharmacology RM1-950
spellingShingle	prolyl hydroxylase domain hypoxia inducible factor erythropoietin iron Therapeutics. Pharmacology RM1-950 Ishii T Tanaka T Nangaku M Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
description	Taisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, JapanCorrespondence: Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 1138655, JapanTel +81-3-3815-5411Fax +81-3-5800-9826Email mnangaku-tky@umin.ac.jpAbstract: Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxia-inducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.Keywords: prolyl hydroxylase domain, hypoxia-inducible factor, erythropoietin, iron
format	article
author	Ishii T Tanaka T Nangaku M
author_facet	Ishii T Tanaka T Nangaku M
author_sort	Ishii T
title	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
title_short	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
title_full	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
title_fullStr	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
title_full_unstemmed	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
title_sort	profile of daprodustat in the treatment of renal anemia due to chronic kidney disease
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f7bc19af972b4ef4b01564c2effb0336
work_keys_str_mv	AT ishiit profileofdaprodustatinthetreatmentofrenalanemiaduetochronickidneydisease AT tanakat profileofdaprodustatinthetreatmentofrenalanemiaduetochronickidneydisease AT nangakum profileofdaprodustatinthetreatmentofrenalanemiaduetochronickidneydisease
_version_	1718391760275636224

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease

Ejemplares similares